PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026
PolyPid will present an oral late-breaking presentation at IDWeek 2026 on pooled microbiology data for D-PLEX100 from three randomized trials covering 2,185 patients. In the 134-patient culture-positive SSI subset, heavy bacterial growth was less frequent with D-PLEX100 plus standard of care than with standard of care alone (16% vs 27%, p=0.034), and breakthrough infections occurred later (median 10.0 vs 6.5 days), with no increase in multidrug-resistant organisms.
Key figures
- Drug Name
- D-PLEX100 (doxycycline, Kynatrix delivery)
- Phase Of Trial
- pooled Phase 2 and two Phase 3 (SHIELD I, SHIELD II)
- Pooled population
- 2185
- Culture positive ssi subset
- 134
- Shield ii relative risk reduction
- 60% (p=0.0013)
- Heavy bacterial growth dplex vs soc
- 16% vs 27% (p=0.034)
- Median time to breakthrough ssi days
- 10.0 vs 6.5 (p<0.001)
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.